Aldagen, Inc. Pulls $80.5 Million IPO

Wed, 06 Apr 2011 12:00:00 AM GMT

Triangle Business Journal -- Aldagen Inc. has withdrawn its long-awaited $80.5 million IPO.

The Durham-based drug developer filed the withdrawal request with regulators on Tuesday, citing market conditions and its determination that registration of the companys securities is not in the best interest of the company at this time.

Aldagen had filed an S-1 to go public in October...

Ikaria Inc. Withdraws IPO, Leaving Arch, Hutch in the Lurch

Thu, 11 Nov 2010 12:00:00 AM GMT

Xconomy -- Ikaria, the company with the futuristic hibernation-on-demand technology with roots at the Fred Hutchinson Cancer Research Center in Seattle, has withdrawn its IPO plans, according to a report from Dow Jones News Services. Goldman Sachs, an underwriter of the deal, confirmed it has been withdrawn, according to the wire service.

Belgium's Taminco Cancels IPO, Cites Poor Market

Thu, 04 Feb 2010 12:00:00 AM GMT

Alimera Sciences Cancels IPO

Thu, 09 Apr 2009 12:00:00 AM GMT

Private Equity Hub -- Alimera Sciences Inc., an Atlanta-based ophthalmic pharmaceutical company, has withdrawn registration for a $75 million IPO, due to current public market conditions. It had planned to trade on the Nasdaq, with Credit Suisse and Citi serving as co-lead underwriters.

Epocrates Inc. Cancels IPO

Tue, 16 Dec 2008 12:00:00 AM GMT

Epocrates Inc., a San Mateo, Calif.-based provider of clinical information and support tools to healthcare professionals, has withdrawn plans for a $75 million IPO. It had planned to trade on the Nasdaq, with Citi serving as lead underwriter.

Aegerion Pharmaceuticals, Inc. Cancels Another IPO

Mon, 15 Dec 2008 12:00:00 AM GMT

Aegerion Pharmaceuticals Inc., a Bridgewater, N.J.-based drug company focused on cardiovascular and metabolic diseases, has withdrawn registration for an $86.25 million IPO, due to market conditions. This is the second time in as many years that Aegerion has canceled a proposed IPO.

ChemoCentryx, Inc. Cancels IPO

Mon, 17 Nov 2008 12:00:00 AM GMT

PeHUB -- ChemoCentryx Inc., a Mountain View, Calif.-based developer of oral drugs for autoimmune diseases, inflammatory diseases and oncology, has withdrawn registration for a $57.5 million IPO, citing market conditions. The company had planned to trade on the Nasdaq, with Credit Suisse serving as lead underwriter.

CyDex Pharmaceuticals Cancels IPO

Wed, 29 Oct 2008 12:00:00 AM GMT

Private Equity Hub - Oct 29, 2008 - CyDex Pharmaceuticals Inc., a Lenexa, Kansas-based developer of drugs that address limitations of current therapies in selected established, has withdrawn registration of its $50 million IPO. It had planned to trade on the Nasdaq, with Pacific Growth Equities serving as lead underwriter.

Xanodyne Pharmaceuticals, Inc. Cancels IPO Due to "Market Conditions"

Mon, 27 Oct 2008 12:00:00 AM GMT

Xanodyne Pharmaceuticals Inc., a Florence, Ky.-based drug company, has withdrawn registration for an $86.25 million IPO due to market conditions. It had planned to trade on the Nasdaq, with Morgan Stanley and Deutsche Bank Securities serving as co-lead underwriters.

Aldagen, Inc. Files to Withdraw IPO Plans

Wed, 08 Oct 2008 12:00:00 AM GMT

WASHINGTON, Oct 7 (Reuters) - Biopharmaceutical company Aldagen Inc filed with regulators on Tuesday to withdraw its plans for an $80.5 million initial public offering.

INSYS Therapeutics Files to Withdraw IPO Plans

Tue, 09 Sep 2008 12:00:00 AM GMT

NEW YORK, Sept 8 (Reuters) - U.S. biopharmaceutical company Insys Therapeutics Inc filed to withdraw its plans for an $86.3 million initial public offering, citing market conditions.

Codexis Pharmaceuticals Cancels $100 Million IPO

Wed, 03 Sep 2008 12:00:00 AM GMT

Codexis Inc., a Redwood City, Calif.-based provider of solutions for pharma chemical process development and manufacturing, has withdrawn registration for a $100 million IPO. It has planned to trade on the Nasdaq, with Credit Suisse and Goldman Sachs serving as co-lead underwriters. Codexis has raised just over $80 million in VC funding since 2002, from firms like CCTV Investments, CMEA Ventures, Pequot...

Bayhill Therapeutics, Inc. Withdraws IPO Plans

Mon, 30 Jun 2008 12:00:00 AM GMT

WASHINGTON, June 27 (Reuters) - Bayhill Therapeutics Inc filed on Friday to withdraw its plans for an initial public offering, citing unfavorable market conditions.

EDB Singapore and Agency for Science, Technology and Research Release: Singapore Reinforces Position as a Global Site for Pharma & Biotech

Wed, 18 Jun 2008 12:00:00 AM GMT

SAN DIEGO, June 18 /Xinhua-PRNewswire/ -- Singapore has firmly established itself as a leading manufacturing hub in Asia with its strong track record, sophisticated infrastructure, superior IP protection and reliability. Its biomedical sciences manufacturing output expanded four-fold from US$4.4 billion in 2000 to US$17 billion in 2007 at a compounded annual growth rate of 21%, far surpassing...